143 results about "Autoimmune xerostomia" patented technology

The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

The invention relates to a Chinese medicinal preparation for treating nervous headache, which comprises the following raw material medicines: Chinese angelica, bupleurum, root of red-rooted salvia, peach seed, manchurian wildginger, white paeony root, largehead atractylodes rhizome, incised notopterygium rhizome, szechuan lovage rhizome, myrrh, polygalae root, platycladi seed, silktree albizzia bark, tall gastrodia tuber, gambir plant and eucommia bark, wherein for patients who suffer from yin deficiency and yang excess and wind-evil invasion, weeping forsythia, cassia seed, baical skullcap root and dwarf lilyturf tuber are added into the raw material medicines; for patients who suffer from dizziness, vexation, xerostomia and bitterness in mouth and upward invasion of liver-fire, angelica dahurica, common selfheal fruit-spike, prepared tuber of multiflower knotweed and gardenia jasminoides are added into the raw material medicines; and for patients who suffer from insomnia, dreaminess, deficiency of qi and blood stasis, raw rehmannia root, astragalus, spina date seed, curcuma aromatica and tuber feeceflower stem are added into the raw material medicines. In the Chinese medicinal preparation, the selected raw material medicines are mainly used for dispelling wind and eliminating cold, eliminating blood stasis and removing obstruction in channels, invigorating blood circulation, promoting qi and relieving pain, and can address both symptoms and root causes based on the theory with syndrome differentiation. 'Pain onsets when obstructed and goes when passable', so a method for removing obstruction in channels to relieve pain is mainly adopted on treatment. By the Chinese medicinal preparation, the angiokinesis function restores to be normal, branch artery spasm is removed, the blood supply of local tissue restores to be normal, and microcirculation is improved, so that channels and collaterals are dredged to fulfill the aim of 'pain goes when passable'.

New liquid compositions are described for the relief of the xerostomia and the treatment of associated disorders, in which the compositions contain: a) saline saliva substitute agents selected from the group consisting of sodium chloride, potassium chloride, sodium bicarbonate, monobasic potassium phosphate, and dibasic phosphate potassium; b) saliva production stimulation agents selected from the group consisting of citric acid or its alkali metal salts and malic acid or its alkali metal salts; c) oral antiseptics selected from the group consisting of triclosan, chlorhexidine and its salts, benzalkonium and its salts, and cetylpyridinium chloride; d) anticariogenic agents selected from the group consisting of fluoride sodium, sodium monofluorophosphate, and xylitol; and e) oral mucosa protective agents selected from the group consisting of vitamin E acetate, panthenol, dipotassium glycyrrhizinate and extracts of aloe vera. The aforementioned compositions are presented in the form of mouthwashes, sprays, oral gels, and toothpastes.

Compositions having high fluoride ion recovery comprising a hydrocolloid, a heteropolysaccharide, a PVME/MA copolymer, and a fluoride ion source and use thereof, e.g., in the treatment of xerostomia and/or sensitive teeth.

The invention provides a composition for relieving xerostomia and a preparation method thereof. Effective constituents in the composition are one or more of a hyaluronic acid, Pulullan and a polyglutamic acid. The composition has the feature of relieving chronic and transient xerostomia caused by diseases, medicine using, radio therapy, chemotherapy and aging. The composition prepared from raw materials with high biosecurity can lubricate oral cavities and keep the oral cavities moist, and can be prepared into toothpaste, mouthrinse, chewing gum and the like. The prepared composition for relieving xerostomia does not have toxic or side effects on human bodies, and allergy or irritation is avoided.

A sialogogue characterized by comprising polyglutamic acid or its salt. This sialogogue is blended into an oral composition and a food product. This sialogogue is capable of rendering the oral mucosa pleasant even in the case of severe xerostomia.

The present invention provides a liquid preparation composition comprising a solvent and a surfactant dissolving in the solvent, the surface tension of the liquid preparation composition is less than 60mN / m, and the pH of the liquid preparation composition is 5.0-7.4. The present invention also discloses a preparation method of the liquid preparation composition and use of the liquid preparation composition in treatment of otitis media, otitis externa, rhinitis, nasosinusitis, lower respiratory tract inflammation, xerostomia, xerophthalmia and dry noses. The present invention also discloses a preparation comprising the liquid preparation composition. The liquid preparation composition can effectively relieve the otitis media, the otitis externa, the rhinitis, the nasosinusitis, the lower respiratory tract inflammation, the xerostomia, the xerophthalmia, the dry noses and other symptoms, can be used in the form of sprays or liquid droplets, can be applied to an effective site without use of a propellant or an atomization device, is easy to operate, and can effectively avoid stimulation and injury caused by the propellant and use inconvenience of the atomization device.

Compositions for the treatment of xerostomia, and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a film or tablet, such as a double layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions themselves are able to increase the levels of saliva in the mouth without the need for active agents, such sialogogic agents. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa.

A medicament used for prophylactic and/or therapeutic treatment of xerostomia, which is in the form for oral mucosal administration comprising a spirooxathiolane quinuclidine derivative represented by the following general formula (I) or an acid addition salt thereof:

[Formula 1]

(wherein R¹ and R² may be the same or different, and independently represent a hydrogen atom, an alkyl group, a cyclopentyl group, a cyclohexyl group, a monoaryl- or diaryl-substituted methylol group, or an aryl-substituted alkyl group) as an active ingredient.

Novel pharmaceutical composition for accelerating salivation and for prophylaxis and/or treatment of xerostornia, which comprises as an active ingredient a carbostyril compound of the formula (1), wherein R is a halogen atom, and the substitution position of the subsistuent on said carbostyril nucleus is the 3- or 4-position, and the bond between the 3- or 4-positions of the carbostyril nucleus is either a single bond or a double bond, or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention exhibits an accelcrating activity of salivation, and is useful in the prophylaxis or treatment of Xerostomia or hyposalivation.

The invention relates to artificial saliva, which comprises a plurality of inorganic salt, HPMC, a preservative, a flavoring agent and other components. The artificial saliva has the following advantages that: (1) the artificial saliva can rapidly improve symptoms of a patient suffering from xerostomia, and can maintain the function in a longer period; (2) the artificial saliva has good stability; and (3) the artificial saliva has a good mouthfeel when in use.

The present invention relates to an oral composition and method for alleviating the symptoms associated with xerostomia using encapsulated cation-releasing compounds formulated either intimately together or in separate compartments in a composition containing cation-sensitive mucoadhesive polymers.

The present invention relates to compositions and comestibles that impart a mouth-moistening effect when orally consumed by an individual. More specifically, the compositions of the present invention may include a blend of components, such as a sweetening composition, food-grade acid composition and a cooling agent, that reduces or eliminates the perception of mouth dryness in an individual. The present invention also provides methods for preparing such comestibles, as well as methods of treating xerostomia by orally administering such comestibles.